An observational registry study on the use of ENCRUSO RAL- Everolimus eluting stent in indian populatio
- Conditions
- Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery
- Registration Number
- CTRI/2022/03/040921
- Lead Sponsor
- ano Therapeutics Private Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
1.Male or female patient who is 18 years and above
2.Patients undergoing percutaneous coronary intervention with Encruso RAL-Everolimus Eluting Coronary Stent System
3.Patient or legal guardian understands the study requirements and provides written informed consent
4.Patient who is on dual antiplatelet therapy for at least 6 months post procedure
1.Patient has known hypersensitivity or allergies to Aspirin, Heparin,Clopidogrel, Ticlopidine, Everolimus or similar drugs, or any other
analogue or derivative, cobalt, chromium, or contrast media
2.Patient with life expectancy less than 2 years
3.Pregnant and lactating females or planning to become pregnant while in the study
4.Patient currently participating in another investigational drug or device clinical trial
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method